Other · developed by Zai Lab
ZL-1102 is a topical gel formulated at 1% and 3% w/w and applied twice or once daily. It is being studied in plaque psoriasis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06380907 | Phase 2 | Plaque Psoriasis | Terminated | ZLAB |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Plaque Psoriasis
Updated Nov 1, 2026. Something wrong or missing? Report it on the ZLAB page.
See ZLAB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ZLAB catalysts and pipeline →